Preventative drugs looking to access the US FDA's new Limited Population Antibacterial Drug (LPAD) pathway should help patients with no other options, not necessarily address rare infections, the agency says in a draft guidance.
LPAD is intended to encourage more antibacterial and antifungal development by allowing approvals for small populations with serious and life-threatening conditions with an unmet need. FDA said in